Immunomedics, Inc. (IMMU) Financial Statements (2024 and earlier)
Company Profile
Business Address |
300 AMERICAN RD MORRIS PLAINS, NJ 07950 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
6/30/2020 MRQ | 12/31/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments, including: | 613,178 | 638,800 | 154,900 | 50,600 | 99,600 | 41,800 | |||
Cash and cash equivalents | 608,628 | 612,057 | 43,394 | 13,204 | 13,453 | 6,961 | |||
Short-term investments | 4,550 | 26,745 | 111,508 | 37,424 | 86,166 | ||||
Other undisclosed cash, cash equivalents, and short-term investments | (2) | (2) | (28) | (18) | 34,839 | ||||
Receivables | 295 | 46 | 502 | 751 | 1,203 | 675 | |||
Inventory, net of allowances, customer advances and progress billings | 580 | 351 | 584 | 779 | |||||
Inventory | 580 | 351 | 584 | 779 | |||||
Prepaid expense | 21,818 | 3,803 | 891 | 1,038 | 1,136 | 972 | |||
Other current assets | 3,413 | 5,730 | 423 | 184 | 946 | 181 | |||
Other undisclosed current assets | 2 | 2 | 28 | 18 | 336 | ||||
Total current assets: | 638,704 | 648,380 | 157,298 | 52,951 | 103,487 | 44,742 | |||
Noncurrent Assets | |||||||||
Property, plant and equipment | 32,762 | 15,733 | 5,245 | 3,969 | 2,242 | 1,895 | |||
Regulated entity, other noncurrent assets | 3,375 | ||||||||
Other noncurrent assets | 256 | 60 | 30 | 30 | 30 | 30 | |||
Other undisclosed noncurrent assets | (3,355) | 176 | |||||||
Total noncurrent assets: | 33,018 | 15,793 | 5,275 | 3,999 | 2,292 | 2,102 | |||
TOTAL ASSETS: | 671,722 | 664,173 | 162,573 | 56,950 | 105,780 | 46,844 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 60,860 | 31,664 | 31,367 | 15,188 | 11,808 | 6,244 | |||
Interest and dividends payable | 1,768 | 1,768 | 1,821 | ||||||
Employee-related liabilities | 7,403 | 1,148 | 600 | 688 | |||||
Accounts payable | 37,758 | 24,818 | 5,222 | 5,350 | 3,284 | ||||
Accrued liabilities | 101 | ||||||||
Other undisclosed accounts payable and accrued liabilities | 15,699 | 6,846 | 24,377 | 6,922 | 6,002 | 5,556 | |||
Debt | 7,443 | ||||||||
Deferred revenue and credits | ✕ | ✕ | 94 | 171 | 235 | 272 | |||
Other undisclosed current liabilities | 3,455 | 11,982 | 90,706 | 240 | |||||
Total current liabilities: | 71,758 | 43,740 | 122,244 | 15,424 | 12,080 | 6,484 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 9,965 | 19,763 | 98,084 | 97,354 | 96,625 | ||||
Long-term debt, excluding current maturities | 19,763 | 98,084 | 97,354 | 96,625 | |||||
Liabilities, other than long-term debt | 74,965 | 1,987 | 1,708 | 1,699 | 1,600 | 1,500 | |||
Deferred revenue | 65,000 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
Other liabilities | 9,965 | 1,987 | 1,708 | 1,699 | 1,600 | 1,500 | |||
Operating lease, liability | 9,965 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
Other undisclosed noncurrent liabilities | 247,804 | 198,998 | |||||||
Total noncurrent liabilities: | 332,734 | 220,748 | 99,792 | 99,054 | 98,224 | 1,500 | |||
Total liabilities: | 404,492 | 264,488 | 222,037 | 114,477 | 110,304 | 7,985 | |||
Equity | |||||||||
Equity, attributable to parent, including: | 268,261 | 400,507 | (58,692) | (56,816) | (3,913) | 39,350 | |||
Common stock | 2,125 | 1,868 | 1,103 | 959 | 945 | 931 | |||
Treasury stock, value | (2,095) | (458) | (458) | (458) | (458) | (458) | |||
Additional paid in capital | 1,579,205 | 1,194,998 | 462,666 | 311,321 | 305,229 | 300,081 | |||
Accumulated other comprehensive income (loss) | (568) | (353) | (303) | (132) | (161) | 262 | |||
Accumulated deficit | (1,310,406) | (795,548) | (521,711) | (368,505) | (309,468) | (261,466) | |||
Other undisclosed equity, attributable to parent | 10 | ||||||||
Equity, attributable to noncontrolling interest | (1,031) | (821) | (771) | (711) | (612) | (490) | |||
Total equity: | 267,230 | 399,686 | (59,463) | (57,527) | (4,525) | 38,859 | |||
TOTAL LIABILITIES AND EQUITY: | 671,722 | 664,173 | 162,573 | 56,950 | 105,780 | 46,844 |
Income Statement (P&L) ($ in thousands)
6/30/2020 TTM | 12/31/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 295 | 2,156 | 3,091 | 3,233 | 5,664 | 9,042 | ||
Revenue, net | ✕ | ✕ | 2,156 | 3,091 | 3,233 | 5,653 | 9,042 | |
Cost of revenue (Cost of Goods and Services Sold) | (614) | (483) | (1,159) | (1,528) | ||||
Gross profit: | 295 | 1,542 | 2,609 | 2,074 | 5,664 | 7,514 | ||
Operating expenses | (325,133) | (142,590) | (81,758) | (61,082) | (52,186) | (43,703) | ||
Other undisclosed operating income | 282,095 | 302 | 609 | |||||
Operating income (loss): | (324,838) | 141,047 | (79,150) | (59,008) | (46,220) | (35,580) | ||
Nonoperating income (expense) (Gain (Loss), Foreign Currency Transaction, before Tax) | 81 | 23 | (40) | (1) | 1 | |||
Interest and debt expense | (40,337) | (23,255) | (5,480) | (5,480) | (2,091) | |||
Other undisclosed income from continuing operations before equity method investments, income taxes | 56 | |||||||
Income (loss) from continuing operations before equity method investments, income taxes: | (365,175) | 117,874 | (84,606) | (64,527) | (48,311) | (35,523) | ||
Other undisclosed income (loss) from continuing operations before income taxes | 7,856 | (391,605) | (68,639) | 338 | 246 | |||
Loss from continuing operations before income taxes: | (357,319) | (273,731) | (153,245) | (64,190) | (48,066) | (35,523) | ||
Income tax expense (benefit) | (156) | (21) | 5,054 | (58) | (8) | |||
Loss from continuing operations: | (357,319) | (273,887) | (153,266) | (59,136) | (48,124) | (35,531) | ||
Loss before gain (loss) on sale of properties: | (357,319) | (273,887) | (153,266) | (59,136) | (48,124) | (35,531) | ||
Net loss: | (357,319) | (273,887) | (153,266) | (59,136) | (48,124) | (35,531) | ||
Net income attributable to noncontrolling interest | 129 | 50 | 60 | 99 | 122 | 105 | ||
Net loss available to common stockholders, diluted: | (357,190) | (273,837) | (153,206) | (59,037) | (48,002) | (35,426) |
Comprehensive Income ($ in thousands)
6/30/2020 TTM | 12/31/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (357,319) | (273,887) | (153,266) | (59,136) | (48,124) | (35,531) | ||
Other comprehensive income (loss) | (217) | (50) | (170) | 29 | (423) | 100 | ||
Other undisclosed comprehensive income | 35,537 | |||||||
Comprehensive income (loss): | (357,536) | (273,937) | (153,437) | (59,107) | (48,547) | 105 | ||
Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 129 | 50 | 60 | 99 | 122 | (105) | ||
Other undisclosed comprehensive loss, net of tax, attributable to parent | (35,326) | |||||||
Comprehensive loss, net of tax, attributable to parent: | (357,407) | (273,887) | (153,376) | (59,008) | (48,425) | (35,326) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.